Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

Are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) associated with improved limb, cardiovascular, and kidney outcomes compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and prior major adverse limb events?In this cohort study of 17 288 patients, the use of GLP-1 RAs was associated with significantly lower risks of limb events, amputation, cardiovascular events, progression to dialysis, and all-cause mortality compared with DPP-4 inhibitors.These findings suggest that GLP-1 RAs may offer important protective benefits for high-risk patients with diabetes and prior limb events, supporting their preferential use in secondary prevention.

Corresponding Author: Pao-Hsien Chu, MD, The Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, 199 Tun-Hwa N Rd, Taipei 105, Taiwan (taipei.chu@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.